Form EFFECT Neuphoria Therapeutics
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 27, 2024 |
| Accession Number: | 0001213900-24-111996 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TCL Solar C2 back-contact panels arrive in Europe, open for order
- Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
- Largo Announces Strategic Focus on Higher-Margin Products; Provides Update on Copper-Platinum Group Metal Margins and Potential Expansion; and Further Advances Debt Restructuring
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
